TAK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

1.21T

+5.32%

1.08T

+2.16%

1.15T

+3.87%

Estimates Revision

The market is revising Downward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 18.96%.

Revenue Estimates for FY2026

Revise Downward

-0.75%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-19.47%

In Past 3 Month

Stock Price

Go Up

+18.96%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

H.C. Wainwright

Buy

maintain

$97

2025-12-30

Reason

H.C. Wainwright

Price Target

$97

2025-12-30

maintain

Buy

Reason

H.C. Wainwright says Xoma (XOMA) took "a nice ride down the creativity road again with nice pipeline expansion," after the company announced an expanded relationship with partner Takeda (TAK). The deal with Takeda is highlighted by no cash out from Xoma for bringing in nine assets, the firm notes. This was accomplished by only marginally reducing Xoma's royalty/milestone share in Takeda's mezagitamab. Wainwright maintains its positive view here on the depth and breadth of Xoma's partnered assets as well as the ongoing creativity of transaction the company consummates, and looks forward to a transactional and royalty growing 2026. The firm has a Buy rating on Xoma with a price target of $97 on the shares.

JPMorgan

Neutral

maintain

$34 -> $35

2025-09-09

Reason

JPMorgan

Price Target

$34 -> $35

2025-09-09

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm sees see alixorexton as well-positioned in narcolepsy type I based on detailed results from the Phase II Vibrance-1 study. Alixorexton delivered a profile broadly inline with expectations with efficacy that generally looks better than Takeda's (TAK) Phase III data for oveporexton, the analyst tells investors in a research note. JPMorgan upped its probability of sucess for alixorexton in narcolepsy type I to 75% from 70% following the data.

Needham

Buy

downgrade

$45 -> $43

2025-09-09

Reason

Needham

Price Target

$45 -> $43

2025-09-09

downgrade

Buy

Reason

Needham lowered the firm's price target on Alkermes (ALKS) to $43 from $45 and keeps a Buy rating on the shares following Phase 2 data from the Vibrance-1 study. The firm reduced aliorexton's peak market share in narcolepsy type I by 10% to reflect its safety profile of blurred vision adverse events. The events may dissuade some physicians from using aliorexton as their first choice, especially in narcolepsy type I, given Takeda's (TAK) first-to-market position, the analyst tells investors in a research note. However, Needham continues to see valuation upside for Alkermes, believing alixorexton can have meaningful market share.

BofA

Neutral

maintain

2025-07-21

Reason

BofA

Price Target

2025-07-21

maintain

Neutral

Reason

BofA keeps a Neutral rating on Alkermes (ALKS) after the company reported Phase 2 results from the Vibrance-1 study evaluating its orexin-receptor 2 agonist in narcolepsy type1 patients. The study validates ALKS2680 as an active drug in narcolepsy, the analyst tells investors in a research note. However, the press release provided limited details on effect size and safety, which leaves outstanding questions such as strength of the cataplexy data and competitiveness versus Takeda's (TAK) TAK-861, contends BofA. The firm cites the limited data disclosure to the stock's selloff today. Alkermes in morning trading is down 7% to $27.09.

Needham

Buy

maintain

$270 -> $300

2025-05-29

Reason

Needham

Price Target

$270 -> $300

2025-05-29

maintain

Buy

Reason

Needham raised the firm's price target on Veeva (VEEV) to $300 from $270 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. Despite concerns related to Salesforce's (CRM) recent announcement of winning Takeda (TAK) for CRM, Veeva is executing well on the conversion to Vault, with over 200 customers expected to be live by company's summit next spring, the analyst tells investors in a research note. Veeva also believes that custom builds for companies like Takeda may prove too costly, leading the company to see opportunities for competitive win backs, the firm added.

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 31.86, compared to its 5-year average forward P/E of 27.13. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

27.13

Current PE

31.86

Overvalued PE

40.04

Undervalued PE

14.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.39

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

10.55

Undervalued EV/EBITDA

8.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.58

Current PS

0.00

Overvalued PS

1.73

Undervalued PS

1.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TAK News & Events

Events Timeline

No data

News

7.5

01-08Yahoo Finance

Halozyme and Takeda Sign Exclusive Collaboration for ENTYVIO Development

9.0

01-05NASDAQ.COM

Takeda Submits NDA for Rusfertide, Potential $400M Opt-Out Payment

9.0

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

People Also Watch

Frequently Asked Questions

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 16.31 USD — it has decreased -0.37 % in the last trading day.

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

What is the price predicton of TAK Stock?

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.11T USD, decreased -5.38 % YoY.

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -7.48 USD, decreased -113.08 % YoY.

What changes have occurred in the market's expectations for Takeda Pharmaceutical Co Ltd (TAK)'s fundamentals?

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of January 10 2026.

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 51.90B USD.